ARA 290 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
84	サルコイドーシス	2

84. サルコイドーシス

---

臨床試験数 : 149 /  薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02039687 (ClinicalTrials.gov)	January 2014	16/1/2014	Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis	A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis	Neuropathy of Sarcoidosis	Drug: ARA 290;Other: Placebo	Araim Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	64	Phase 2	United States;Netherlands
2	EUCTR2013-003016-45-NL (EUCTR)	11/09/2013	15/08/2013	study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients.	A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis - DOSARA	small fiber neuropathy;Therapeutic area: Body processes [G] - Biological Phenomena [G16]	Product Name: ARA 290 Product Code: ARA 290 INN or Proposed INN: ARA 290	Araim Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 2	United States;Netherlands